Get the Stockscreener App
19.52
2.25%
0.43
After Hours:
19.91
0.39
+2.00%
Spyglass Pharma Inc stock is traded at $19.52, with a volume of 106.21K.
It is up +2.25% in the last 24 hours and up +3.94% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$19.09
Open:
$19.1
24h Volume:
106.21K
Relative Volume:
1.09
Market Cap:
$652.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.8836
EPS:
-5.0262
Net Cash Flow:
-
1W Performance:
-12.31%
1M Performance:
+3.94%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$18.88
$21.07
1-Week Range:
$18.56
$22.80
52-Week Range:
$17.06
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Name
Spyglass Pharma Inc
Sector
Industry
Phone
949-284-6904
Address
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
19.52 | 638.24M | 0 | 0 | 0 | -5.0262 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | Citigroup | Buy |
| Mar-03-26 | Initiated | Jefferies | Buy |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Stifel | Buy |
Spyglass Pharma Inc Stock (SGP) Latest News
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to book forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to earnings forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to EBIT forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Fails to Dampen Investor OptimismRevenue Miss Report - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index - marketscreener.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SpyGlass Taps Shannon Treviño as General Counsel - Orange County Business Journal
SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans. - Pluang
SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com - Investing.com Nigeria
SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel - marketscreener.com
SpyGlass Pharma appoints Shannon Treviño as general counsel - Investing.com
SpyGlass Pharma Appoints Shannon Treviño as General Counsel - GlobeNewswire
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesAnnual Report - dars.gov.et
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - VisionMonday.com
SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com - Investing.com South Africa
SpyGlass Pharma appoints Mike Pinder as VP of marketing - Investing.com
SpyGlass Pharma (SGP) Slides 2.29% as Stock Approaches Critical Support at $17.0Liquidity Sweep - dars.gov.et
SGP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesCapex Guidance - dars.gov.et
SGPSpyGlass Pharma Inc Stock Price and Quote - Finviz
SpyGlass Pharma to Participate in Upcoming Investor Conferences - Sahm
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - GlobeNewswire
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
Spyglass Pharma Inc Stock (SGP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyglass Pharma Inc Stock (SGP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):